Conflict of interest
Venetoclax is being developed in collaboration between AbbVie and Genentech. Ibrutinib is being developed in collaboration between AbbVie and Janssen Research & Development, LLC. The study sponsor funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data, and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Daniel Roybal, PhD, of Bio Connections, LLC, funded by AbbVie.